Ligand Reports First Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Travere Therapeutics (TVTX) Tops Q1 EPS by 115c
May 4, 2023 5:02 PM EDTTravere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of ($0.09), $1.15 better than the analyst estimate of ($1.24). Revenue for the quarter came in at $44 million versus the consensus estimate of $50.6 million.
For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.
... MoreLigand Pharma (LGND) Tops Q1 EPS by $1.42; Offers FY23 Guidance
May 4, 2023 4:56 PM EDTLigand Pharma (NASDAQ: LGND) reported Q1 EPS of $2.28, $1.42 better than the analyst estimate of $0.86. Revenue for the quarter came in at $44 million versus the consensus estimate of $32 million.
GUIDANCE:
Ligand Pharma sees FY2023 EPS of $4.60-$4.75, versus the consensus of... More
